首页 > 最新文献

World Journal of Nephrology最新文献

英文 中文
Dehydration and volume depletion: How to handle the misconceptions. 脱水和体积损耗:如何处理误解。
Pub Date : 2019-01-21 DOI: 10.5527/wjn.v8.i1.23
Muhammad Asim, Mohamad M Alkadi, Hania Asim, Adil Ghaffar

Dehydration and volume depletion describe two distinct body fluid deficit disorders with differing pathophysiology, clinical manifestations and treatment approaches. However, the two are often confused or equated with each other. Here, we address a number of commonly encountered misconceptions about body-fluid deficit disorders, analyse their origins and propose approaches to overcome them.

脱水和容量耗竭描述了两种不同的体液缺乏症,具有不同的病理生理、临床表现和治疗方法。然而,这两者经常被混淆或等同起来。在这里,我们解决了一些常见的误解关于体液缺乏症,分析他们的起源和建议的方法来克服他们。
{"title":"Dehydration and volume depletion: How to handle the misconceptions.","authors":"Muhammad Asim,&nbsp;Mohamad M Alkadi,&nbsp;Hania Asim,&nbsp;Adil Ghaffar","doi":"10.5527/wjn.v8.i1.23","DOIUrl":"https://doi.org/10.5527/wjn.v8.i1.23","url":null,"abstract":"<p><p>Dehydration and volume depletion describe two distinct body fluid deficit disorders with differing pathophysiology, clinical manifestations and treatment approaches. However, the two are often confused or equated with each other. Here, we address a number of commonly encountered misconceptions about body-fluid deficit disorders, analyse their origins and propose approaches to overcome them.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"8 1","pages":"23-32"},"PeriodicalIF":0.0,"publicationDate":"2019-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v8.i1.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36966245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Clear cell papillary renal cell carcinoma: A case report and review of the literature. 透明细胞乳头状肾细胞癌1例报告及文献复习。
Pub Date : 2018-12-17 DOI: 10.5527/wjn.v7.i8.155
Sung Han Kim, Whi-An Kwon, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung

Clear cell papillary renal cell carcinoma (ccpRCC) was recently established as a distinct type of epithelial neoplasm by the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Here, we report a case of partial nephrectomy for a ccpRCC detected during the routine follow-up of a previously treated liposarcoma in a 70-year-old male patient. The patient was referred to the urology department for a right-sided renal mass (size: 2 cm) detected during routine annual imaging follow-up for a malignant right inguinal fibrous histocytoma and liposarcoma that had been diagnosed 6 and 4 years earlier, respectively, and treated with surgery and adjuvant radiation therapy. Following partial nephrectomy, the renal mass was pathologically diagnosed as ccpRCC, and immunohistochemistry revealed carbonic anhydrase 9 (CA9) expression. No recurrences or metastases were detected on follow-up imaging for 6 months. This is the first report of partial nephrectomy for incidentally discovered CA9-positive ccpRCC.

透明细胞乳头状肾细胞癌(ccpRCC)最近被国际泌尿病理学会温哥华肾肿瘤分类确定为一种独特的上皮肿瘤。在此,我们报告一例70岁男性患者在既往治疗过的脂肪肉瘤的常规随访中发现的ccpRCC部分肾切除术。患者因右腹股沟恶性纤维组织细胞瘤和脂肪肉瘤在常规年度影像学随访中发现右侧肾肿块(大小:2cm)而转至泌尿科,分别于6年和4年前诊断,并接受手术和辅助放射治疗。部分肾切除术后,病理诊断肾肿块为ccpRCC,免疫组化显示碳酸酐酶9 (CA9)表达。随访6个月未见复发或转移。这是偶然发现的ca9阳性ccpRCC部分切除的首例报道。
{"title":"Clear cell papillary renal cell carcinoma: A case report and review of the literature.","authors":"Sung Han Kim,&nbsp;Whi-An Kwon,&nbsp;Jae Young Joung,&nbsp;Ho Kyung Seo,&nbsp;Kang Hyun Lee,&nbsp;Jinsoo Chung","doi":"10.5527/wjn.v7.i8.155","DOIUrl":"https://doi.org/10.5527/wjn.v7.i8.155","url":null,"abstract":"<p><p>Clear cell papillary renal cell carcinoma (ccpRCC) was recently established as a distinct type of epithelial neoplasm by the International Society of Urological Pathology Vancouver Classification of Renal Neoplasia. Here, we report a case of partial nephrectomy for a ccpRCC detected during the routine follow-up of a previously treated liposarcoma in a 70-year-old male patient. The patient was referred to the urology department for a right-sided renal mass (size: 2 cm) detected during routine annual imaging follow-up for a malignant right inguinal fibrous histocytoma and liposarcoma that had been diagnosed 6 and 4 years earlier, respectively, and treated with surgery and adjuvant radiation therapy. Following partial nephrectomy, the renal mass was pathologically diagnosed as ccpRCC, and immunohistochemistry revealed carbonic anhydrase 9 (CA9) expression. No recurrences or metastases were detected on follow-up imaging for 6 months. This is the first report of partial nephrectomy for incidentally discovered CA9-positive ccpRCC.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 8","pages":"155-160"},"PeriodicalIF":0.0,"publicationDate":"2018-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i8.155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36866141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Palliative care for acute kidney injury patients in the intensive care unit. 重症监护病房急性肾损伤患者的姑息治疗。
Pub Date : 2018-12-17 DOI: 10.5527/wjn.v7.i8.148
Vinod Krishnappa, William Hein, Daniel DelloStritto, Mona Gupta, Rupesh Raina

Patients with acute kidney injury (AKI) in the intensive care unit (ICU) are often suitable for palliative care due to the high symptom burden. The role of palliative medicine in this patient population is not well defined and there is a lack of established guidelines to address this issue. Because of this, patients in the ICU with AKI deprived of the most comprehensive or appropriate care. The reasons for this are multifactorial including lack of palliative care training among nephrologists. However, palliative care in these patients can help alleviate symptoms, improve quality of life, and decrease suffering. Palliative care physicians can determine the appropriateness and model of palliative care. In addition to shared decision-making, advance directives should be established with patients early on, with specific instructions regarding dialysis, and those advance directives should be respected.

重症监护病房(ICU)的急性肾损伤(AKI)患者由于症状负担高,通常适合姑息治疗。姑息治疗在这一患者群体中的作用没有得到很好的界定,也缺乏解决这一问题的既定指南。正因为如此,ICU的AKI患者被剥夺了最全面或适当的护理。造成这种情况的原因是多方面的,包括肾病学家缺乏姑息治疗培训。然而,对这些患者进行姑息治疗可以帮助缓解症状,改善生活质量,减少痛苦。姑息治疗医生可以确定姑息治疗的适当性和模式。除了共同决策外,应尽早与患者建立预先指示,对透析有具体指示,并应尊重这些预先指示。
{"title":"Palliative care for acute kidney injury patients in the intensive care unit.","authors":"Vinod Krishnappa,&nbsp;William Hein,&nbsp;Daniel DelloStritto,&nbsp;Mona Gupta,&nbsp;Rupesh Raina","doi":"10.5527/wjn.v7.i8.148","DOIUrl":"https://doi.org/10.5527/wjn.v7.i8.148","url":null,"abstract":"<p><p>Patients with acute kidney injury (AKI) in the intensive care unit (ICU) are often suitable for palliative care due to the high symptom burden. The role of palliative medicine in this patient population is not well defined and there is a lack of established guidelines to address this issue. Because of this, patients in the ICU with AKI deprived of the most comprehensive or appropriate care. The reasons for this are multifactorial including lack of palliative care training among nephrologists. However, palliative care in these patients can help alleviate symptoms, improve quality of life, and decrease suffering. Palliative care physicians can determine the appropriateness and model of palliative care. In addition to shared decision-making, advance directives should be established with patients early on, with specific instructions regarding dialysis, and those advance directives should be respected.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 8","pages":"148-154"},"PeriodicalIF":0.0,"publicationDate":"2018-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4d/ad/WJN-7-148.PMC6305526.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36866140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Awakening the sleeping kidney in a dialysis-dependent patient with fibromuscular dysplasia: A case report and review of literature. 唤醒透析依赖性纤维肌肉发育不良患者的睡眠肾:1例报告及文献复习。
Pub Date : 2018-11-24 DOI: 10.5527/wjn.v7.i7.143
Mogamat-Yazied Chothia, Mogamat Razeen Davids, Raisa Bhikoo

Renal artery stenosis is a common cause of secondary hypertension and chronic kidney disease. We present here a case of fibromuscular dysplasia that was treated with surgical revascularization, resulting in recovery of kidney function with eventual cessation of chronic dialysis. The case involves a 25-year-old female with coincidentally discovered hypertension, who underwent further investigations revealing a diagnosis of renal artery stenosis due to fibromuscular dysplasia. She subsequently developed two episodes of malignant hypertension, with flash pulmonary oedema and worsening renal failure that resulted in dialysis dependence. After evidence was obtained that the right kidney was still viable, a revascularization procedure was performed, improving blood pressure control and restoring kidney function, thereby allowing dialysis to be stopped. This case highlights the importance of evaluating patients with renal artery stenosis for revascularization before committing them to a life of chronic dialysis.

肾动脉狭窄是继发性高血压和慢性肾脏疾病的常见原因。我们在这里提出一个病例的纤维肌肉发育不良,通过手术血运重建术治疗,导致肾功能恢复,最终停止慢性透析。该病例涉及一名25岁的女性,她偶然发现高血压,她接受了进一步的检查,诊断为因纤维肌肉发育不良引起的肾动脉狭窄。随后,她出现了两次恶性高血压发作,并伴有突发性肺水肿和肾功能衰竭加重,导致透析依赖。在获得证据表明右肾仍然存活后,进行血运重建手术,改善血压控制并恢复肾功能,从而允许停止透析。本病例强调了在对肾动脉狭窄患者进行慢性透析治疗前评估其血运重建术的重要性。
{"title":"Awakening the sleeping kidney in a dialysis-dependent patient with fibromuscular dysplasia: A case report and review of literature.","authors":"Mogamat-Yazied Chothia,&nbsp;Mogamat Razeen Davids,&nbsp;Raisa Bhikoo","doi":"10.5527/wjn.v7.i7.143","DOIUrl":"https://doi.org/10.5527/wjn.v7.i7.143","url":null,"abstract":"<p><p>Renal artery stenosis is a common cause of secondary hypertension and chronic kidney disease. We present here a case of fibromuscular dysplasia that was treated with surgical revascularization, resulting in recovery of kidney function with eventual cessation of chronic dialysis. The case involves a 25-year-old female with coincidentally discovered hypertension, who underwent further investigations revealing a diagnosis of renal artery stenosis due to fibromuscular dysplasia. She subsequently developed two episodes of malignant hypertension, with flash pulmonary oedema and worsening renal failure that resulted in dialysis dependence. After evidence was obtained that the right kidney was still viable, a revascularization procedure was performed, improving blood pressure control and restoring kidney function, thereby allowing dialysis to be stopped. This case highlights the importance of evaluating patients with renal artery stenosis for revascularization before committing them to a life of chronic dialysis.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 7","pages":"143-147"},"PeriodicalIF":0.0,"publicationDate":"2018-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i7.143","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36748538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Confounding risk factors and preventative measures driving nephrolithiasis global makeup. 混杂的危险因素和预防措施驱动肾结石的全球构成。
Pub Date : 2018-11-24 DOI: 10.5527/wjn.v7.i7.129
Samuel Shin, Aneil Srivastava, Nazira A Alli, Bidhan C Bandyopadhyay

Nephrolithiasis is increasing in developed and developing countries at an alarming rate. With the global spike in kidney stone diseases, it is crucial to determine what risk factors are influencing the current global landscape for kidney stones. Our aims for this review are: to identity and analyze the four categories of risk factors in contributing to the global scale of stone formation: lifestyle, genetics, diet, and environment; and discuss preventative measures for kidney stone formation. We also performed data search through the published scientific literature, i.e., PubMed® and found that there is a significant link between lifestyle and obesity with cases of calcium stones. Food and Agriculture Organization of the United Nations and World Health Organization factor indicators for dietary intake and obesity, along with climate data were used to create the projected total risk world map model for nephrolithiasis risk. Complete global analyses of nephrolithiasis deplete of generalizations is nearly insurmountable due to limited sources of medical and demographic information, but we hope this review can provide further elucidation into confounding risk factors and preventative measures for global nephrolithiasis analysis.

在发达国家和发展中国家,肾结石正在以惊人的速度增加。随着肾结石疾病的全球激增,确定影响肾结石当前全球格局的风险因素至关重要。我们这篇综述的目的是:识别和分析导致全球范围内结石形成的四类风险因素:生活方式、遗传、饮食和环境;并探讨肾结石形成的预防措施。我们还通过已发表的科学文献(即PubMed®)进行了数据搜索,发现生活方式和肥胖与钙结石病例之间存在显著联系。利用联合国粮食及农业组织和世界卫生组织的饮食摄入和肥胖因素指标以及气候数据,建立了肾结石风险的预计总风险世界地图模型。由于医学和人口统计信息来源有限,对全球肾结石的全面分析几乎是不可能的,但我们希望这篇综述可以进一步阐明全球肾结石分析的混杂危险因素和预防措施。
{"title":"Confounding risk factors and preventative measures driving nephrolithiasis global makeup.","authors":"Samuel Shin,&nbsp;Aneil Srivastava,&nbsp;Nazira A Alli,&nbsp;Bidhan C Bandyopadhyay","doi":"10.5527/wjn.v7.i7.129","DOIUrl":"https://doi.org/10.5527/wjn.v7.i7.129","url":null,"abstract":"<p><p>Nephrolithiasis is increasing in developed and developing countries at an alarming rate. With the global spike in kidney stone diseases, it is crucial to determine what risk factors are influencing the current global landscape for kidney stones. Our aims for this review are: to identity and analyze the four categories of risk factors in contributing to the global scale of stone formation: lifestyle, genetics, diet, and environment; and discuss preventative measures for kidney stone formation. We also performed data search through the published scientific literature, <i>i.e</i>., PubMed<sup>®</sup> and found that there is a significant link between lifestyle and obesity with cases of calcium stones. Food and Agriculture Organization of the United Nations and World Health Organization factor indicators for dietary intake and obesity, along with climate data were used to create the projected total risk world map model for nephrolithiasis risk. Complete global analyses of nephrolithiasis deplete of generalizations is nearly insurmountable due to limited sources of medical and demographic information, but we hope this review can provide further elucidation into confounding risk factors and preventative measures for global nephrolithiasis analysis.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 7","pages":"129-142"},"PeriodicalIF":0.0,"publicationDate":"2018-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i7.129","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36748537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 19
Oral alkali therapy and the management of metabolic acidosis of chronic kidney disease: A narrative literature review. 口服碱疗法与慢性肾病代谢性酸中毒的治疗:叙述性文献综述。
Pub Date : 2018-10-10 DOI: 10.5527/wjn.v7.i6.117
Adeel Rafi Ahmed, David Lappin

Chronic metabolic acidosis is a common complication seen in advanced chronic kidney disease (CKD). There is currently no consensus on its management in the Republic of Ireland. Recent trials have suggested that appropriate active management of metabolic acidosis through oral alkali therapy and modified diet can have a deterring impact on CKD progression. The potential benefits of treatment include preservation of bone health and improvement in muscle function; however, present data is limited. This review highlights the current evidence, available primarily from randomised control trials (RCTs) over the last decade, in managing the metabolic acidosis of CKD and outlines ongoing RCTs that are promising. An economic perspective is also briefly discussed to support decision-making.

慢性代谢性酸中毒是晚期慢性肾脏疾病(CKD)的常见并发症。目前在爱尔兰共和国对其管理没有达成共识。最近的试验表明,通过口服碱治疗和改变饮食对代谢性酸中毒进行适当的积极管理可以对CKD的进展产生阻止作用。治疗的潜在益处包括保持骨骼健康和改善肌肉功能;然而,目前的资料有限。本综述重点介绍了过去十年来主要来自随机对照试验(RCTs)的关于CKD代谢性酸中毒管理的现有证据,并概述了正在进行的有希望的随机对照试验。还简要讨论了经济观点,以支持决策。
{"title":"Oral alkali therapy and the management of metabolic acidosis of chronic kidney disease: A narrative literature review.","authors":"Adeel Rafi Ahmed,&nbsp;David Lappin","doi":"10.5527/wjn.v7.i6.117","DOIUrl":"https://doi.org/10.5527/wjn.v7.i6.117","url":null,"abstract":"<p><p>Chronic metabolic acidosis is a common complication seen in advanced chronic kidney disease (CKD). There is currently no consensus on its management in the Republic of Ireland. Recent trials have suggested that appropriate active management of metabolic acidosis through oral alkali therapy and modified diet can have a deterring impact on CKD progression. The potential benefits of treatment include preservation of bone health and improvement in muscle function; however, present data is limited. This review highlights the current evidence, available primarily from randomised control trials (RCTs) over the last decade, in managing the metabolic acidosis of CKD and outlines ongoing RCTs that are promising. An economic perspective is also briefly discussed to support decision-making.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 6","pages":"117-122"},"PeriodicalIF":0.0,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i6.117","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36588163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide. 血液透析患者的碳酸氢盐水平从碳酸镧转变为氢氧化铁。
Pub Date : 2018-10-10 DOI: 10.5527/wjn.v7.i6.123
Aristeidis Stavroulopoulos, Vasiliki Aresti, Christoforos Papadopoulos, Panagiotis Nennes, Polixeni Metaxaki, Anastasios Galinas

Aim: To examine possible alterations in acid-base parameters in patients switching from lanthanum carbonate (LanC) to sucroferric oxyhydroxide (SFOH).

Methods: Fifteen stable hemodialysis patients were switched from LanC to SFOH. Only nine continued on SFOH, three returned to LanC and the other three switched to sevelamer carbonate. The later six patients served as a control group to the SFOH group of nine patients. Blood was sampled on the 3-d and the last 2-d interval of the week prior to switching and six weeks after. Bicarbonate levels (HCO3 -), pH, pO2, pCO2 were measured, and the mean of the two measurements (3-d and 2-d interval) was calculated.

Results: Comparing pre-switching to post-switching measurements in the SFOH group, no statistically significant differences were found in any of the parameters studied. The mean pre-switching HCO3 - was 22.41 ± 1.66 mmol/L and the mean post-switching was 22.62 ± 2.25 mmol/L (P = 0.889). Respectively, the mean pH= 7.38 ± 0.03 vs 7.39 ± 0.03 (P = 0.635), mean pCO2= 38.41 ± 3.29 vs 38.37 ± 3.62 mmHg (P = 0.767), and Phosphate = 1.57 ± 0.27 vs 1.36 ± 0.38mmol/L (P = 0.214). There were not any significant differences when we performed the same analyses in the control group or between the SFOH group and control group. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.

Conclusion: In our small study, switching from LanC to SFOH did not have any significant effect on blood bicarbonate levels and gas analysis, indicating that there is no need to change hemodialysis prescription regarding these parameters.

目的:研究从碳酸镧(LanC)转向氢氧化铁(soh)的患者酸碱参数可能发生的变化。方法:将15例稳定血透患者由LanC转为SFOH。只有9个继续使用SFOH, 3个返回LanC,另外3个切换到七维拉姆碳酸。后6例患者作为SFOH组9例患者的对照组。在切换前一周和切换后六周的3-d和最后2-d间隔抽取血液。测量了碳酸氢盐(HCO3 -)、pH、pO2、pCO2水平,并计算了两者的平均值(三维和二维间隔)。结果:比较SFOH组切换前和切换后的测量结果,在研究的任何参数中均未发现统计学上的显著差异。切换前HCO3 -均值为22.41±1.66 mmol/L,切换后均值为22.62±2.25 mmol/L (P = 0.889)。平均pH= 7.38±0.03 vs 7.39±0.03 (P = 0.635),平均pCO2= 38.41±3.29 vs 38.37±3.62 mmHg (P = 0.767),平均磷酸盐= 1.57±0.27 vs 1.36±0.38mmol/L (P = 0.214)。当我们在对照组或SFOH组与对照组之间进行相同的分析时,没有任何显着差异。无论是切换前的LanC日剂量还是切换后的新粘合剂日剂量与测量参数之间都没有发现相关性。结论:在我们的小型研究中,从LanC切换到SFOH对血液碳酸氢盐水平和气体分析没有任何显著影响,表明无需改变血液透析处方的这些参数。
{"title":"Bicarbonate levels in hemodialysis patients switching from lanthanum carbonate to sucroferric oxyhydroxide.","authors":"Aristeidis Stavroulopoulos,&nbsp;Vasiliki Aresti,&nbsp;Christoforos Papadopoulos,&nbsp;Panagiotis Nennes,&nbsp;Polixeni Metaxaki,&nbsp;Anastasios Galinas","doi":"10.5527/wjn.v7.i6.123","DOIUrl":"https://doi.org/10.5527/wjn.v7.i6.123","url":null,"abstract":"<p><strong>Aim: </strong>To examine possible alterations in acid-base parameters in patients switching from lanthanum carbonate (LanC) to sucroferric oxyhydroxide (SFOH).</p><p><strong>Methods: </strong>Fifteen stable hemodialysis patients were switched from LanC to SFOH. Only nine continued on SFOH, three returned to LanC and the other three switched to sevelamer carbonate. The later six patients served as a control group to the SFOH group of nine patients. Blood was sampled on the 3-d and the last 2-d interval of the week prior to switching and six weeks after. Bicarbonate levels (HCO<sub>3</sub> <sup>-</sup>), pH, pO<sub>2</sub>, pCO<sub>2</sub> were measured, and the mean of the two measurements (3-d and 2-d interval) was calculated.</p><p><strong>Results: </strong>Comparing pre-switching to post-switching measurements in the SFOH group, no statistically significant differences were found in any of the parameters studied. The mean pre-switching HCO<sub>3</sub> <sup>-</sup> was 22.41 ± 1.66 mmol/L and the mean post-switching was 22.62 ± 2.25 mmol/L (<i>P</i> = 0.889). Respectively, the mean pH= 7.38 ± 0.03 <i>vs</i> 7.39 ± 0.03 (<i>P</i> = 0.635), mean pCO<sub>2</sub>= 38.41 ± 3.29 <i>vs</i> 38.37 ± 3.62 mmHg (<i>P</i> = 0.767), and Phosphate = 1.57 ± 0.27 <i>vs</i> 1.36 ± 0.38mmol/L (<i>P</i> = 0.214). There were not any significant differences when we performed the same analyses in the control group or between the SFOH group and control group. No correlations were found, either between pre-switching LanC daily dose or between post-switching daily dose of the new binder and the measured parameters.</p><p><strong>Conclusion: </strong>In our small study, switching from LanC to SFOH did not have any significant effect on blood bicarbonate levels and gas analysis, indicating that there is no need to change hemodialysis prescription regarding these parameters.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 6","pages":"123-128"},"PeriodicalIF":0.0,"publicationDate":"2018-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/98/WJN-7-123.PMC6181871.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36588164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease. 纤维性多囊性肝肾疾病模型中的小分子纤维激酶抑制剂。
Pub Date : 2018-09-07 DOI: 10.5527/wjn.v7.i5.96
Prani Paka, Brian Huang, Bin Duan, Jing-Song Li, Ping Zhou, Latha Paka, Michael A Yamin, Scott L Friedman, Itzhak D Goldberg, Prakash Narayan

Aim: To evaluate the novel platelet-derived growth factor receptor and vascular endothelial growth factor receptor dual kinase inhibitor ANG3070 in a polycystic kidney disease-congenital hepatic fibrosis model.

Methods: At 6 wk of age, PCK rats were randomized to vehicle or ANG3070 for 4 wk. At 10 wk, 24 h urine and left kidneys were collected and rats were continued on treatment for 4 wk. At 14 wk, 24 h urine was collected, rats were sacrificed, and liver and right kidneys were collected for histological evaluation. For Western blot studies, PCK rats were treated with vehicle or ANG3070 for 7 d and sacrificed approximately 30 min after the last treatments.

Results: Compared to the wild-type cohort, the PCK kidney (Vehicle cohort) exhibited a marked increase in kidney and liver mass, hepato-renal cystic volume, hepato-renal fibrosis and hepato-renal injury biomarkers. Intervention with ANG3070 in PCK rats decreased kidney weight, reduced renal cystic volume and reduced total kidney hydroxyproline, indicating significantly reduced rental interstitial fibrosis compared to the PCK-Vehicle cohort. ANG3070 treatment also mitigated several markers of kidney injury, including urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C and interleukin-18 levels. In addition, this treatment attenuated key indices of renal dysfunction, including proteinuria, albuminuria and serum blood urea nitrogen and creatinine, and significantly improved renal function compared to the PCK-Vehicle cohort. ANG3070 treatment also significantly decreased liver enlargement, hepatic lesions, and liver fibrosis, and mitigated liver dysfunction compared to the PCK-Vehicle cohort.

Conclusion: These results suggest that ANG3070 has the potential to slow disease, and may serve as a bridge toward hepato-renal transplantation in patients with fibropolycystic disease.

目的:探讨新型血小板源性生长因子受体和血管内皮生长因子受体双激酶抑制剂ANG3070在多囊肾病-先天性肝纤维化模型中的作用。方法:在6周龄时,将PCK大鼠随机分为对照组和ANG3070组,持续4周。在10周时,收集24 h尿液和左肾,继续给药4周。14周取24 h尿液,处死大鼠,取肝、右肾进行组织学评价。在Western blot研究中,PCK大鼠用载药或ANG3070处理7 d,并在最后一次处理后约30分钟后处死。结果:与野生型队列相比,PCK肾脏(Vehicle队列)的肾脏和肝脏质量、肝肾囊体积、肝肾纤维化和肝肾损伤生物标志物显著增加。与PCK- vehicle队列相比,ANG3070干预PCK大鼠的肾脏重量降低,肾囊体积减小,肾羟脯氨酸总量减少,表明租期间质纤维化明显减少。ANG3070治疗还减轻了几种肾损伤标志物,包括尿中性粒细胞明胶酶相关脂钙素、肾损伤分子-1、胱抑素C和白细胞介素-18水平。此外,与PCK-Vehicle队列相比,该治疗降低了肾功能的关键指标,包括蛋白尿、蛋白尿和血清尿素氮、肌酐,并显著改善了肾功能。与PCK-Vehicle队列相比,ANG3070治疗还显著减少了肝肿大、肝病变和肝纤维化,并减轻了肝功能障碍。结论:这些结果表明ANG3070具有减缓疾病的潜力,可能成为纤维多囊病患者肝肾移植的桥梁。
{"title":"A small molecule fibrokinase inhibitor in a model of fibropolycystic hepatorenal disease.","authors":"Prani Paka,&nbsp;Brian Huang,&nbsp;Bin Duan,&nbsp;Jing-Song Li,&nbsp;Ping Zhou,&nbsp;Latha Paka,&nbsp;Michael A Yamin,&nbsp;Scott L Friedman,&nbsp;Itzhak D Goldberg,&nbsp;Prakash Narayan","doi":"10.5527/wjn.v7.i5.96","DOIUrl":"https://doi.org/10.5527/wjn.v7.i5.96","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the novel platelet-derived growth factor receptor and vascular endothelial growth factor receptor dual kinase inhibitor ANG3070 in a polycystic kidney disease-congenital hepatic fibrosis model.</p><p><strong>Methods: </strong>At 6 wk of age, PCK rats were randomized to vehicle or ANG3070 for 4 wk. At 10 wk, 24 h urine and left kidneys were collected and rats were continued on treatment for 4 wk. At 14 wk, 24 h urine was collected, rats were sacrificed, and liver and right kidneys were collected for histological evaluation. For Western blot studies, PCK rats were treated with vehicle or ANG3070 for 7 d and sacrificed approximately 30 min after the last treatments.</p><p><strong>Results: </strong>Compared to the wild-type cohort, the PCK kidney (Vehicle cohort) exhibited a marked increase in kidney and liver mass, hepato-renal cystic volume, hepato-renal fibrosis and hepato-renal injury biomarkers. Intervention with ANG3070 in PCK rats decreased kidney weight, reduced renal cystic volume and reduced total kidney hydroxyproline, indicating significantly reduced rental interstitial fibrosis compared to the PCK-Vehicle cohort. ANG3070 treatment also mitigated several markers of kidney injury, including urinary neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C and interleukin-18 levels. In addition, this treatment attenuated key indices of renal dysfunction, including proteinuria, albuminuria and serum blood urea nitrogen and creatinine, and significantly improved renal function compared to the PCK-Vehicle cohort. ANG3070 treatment also significantly decreased liver enlargement, hepatic lesions, and liver fibrosis, and mitigated liver dysfunction compared to the PCK-Vehicle cohort.</p><p><strong>Conclusion: </strong>These results suggest that ANG3070 has the potential to slow disease, and may serve as a bridge toward hepato-renal transplantation in patients with fibropolycystic disease.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 5","pages":"96-107"},"PeriodicalIF":0.0,"publicationDate":"2018-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i5.96","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36488714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Unique interstitial miRNA signature drives fibrosis in a murine model of autosomal dominant polycystic kidney disease. 在常染色体显性多囊肾病小鼠模型中,独特的间质miRNA特征驱动纤维化。
Pub Date : 2018-09-07 DOI: 10.5527/wjn.v7.i5.108
Ameya Patil, William E Sweeney, Cynthia G Pan, Ellis D Avner

Aim: To delineate changes in miRNA expression localized to the peri-cystic local microenvironment (PLM) in an orthologous mouse model of autosomal dominant polycystic kidney disease (ADPKD) (mcwPkd1(nl/nl) ).

Methods: We profiled miRNA expression in the whole kidney and laser captured microdissection (LCM) samples from PLM in mcwPkd1(nl/nl) kidneys with Qiagen miScript 384 HC miRNA PCR arrays. The three times points used are: (1) post-natal (PN) day 21, before the development of trichrome-positive areas; (2) PN28, the earliest sign of trichrome staining; and (3) PN42 following the development of progressive fibrosis. PN21 served as appropriate controls and as the reference time point for comparison of miRNA expression profiles.

Results: LCM samples revealed three temporally upregulated miRNAs [2 to 2.75-fold at PN28 and 2.5 to 4-fold (P ≤ 0.05) at PN42] and four temporally downregulated miRNAs [2 to 2.75 fold at PN28 and 2.75 to 5-fold (P ≤ 0.05) at PN42]. Expression of twenty-six miRNAs showed no change until PN42 [six decreased (2.25 to 3.5-fold) (P ≤ 0.05) and 20 increased (2 to 4-fold) (P ≤ 0.05)]. Many critical miRNA changes seen in the LCM samples from PLM were not seen in the contralateral whole kidney.

Conclusion: Precise sampling with LCM identifies miRNA changes that occur with the initiation and progression of renal interstitial fibrosis (RIF). Identification of the target proteins regulated by these miRNAs will provide new insight into the process of fibrosis and identify unique therapeutic targets to prevent or slow the development and progression of RIF in ADPKD.

目的:研究常染色体显性多囊肾病(ADPKD)小鼠模型(mcwPkd1(nl/nl))中定位于囊周局部微环境(PLM)的miRNA表达的变化。方法:采用Qiagen miScript 384 HC miRNA PCR阵列对mcwPkd1(nl/nl)肾脏PLM的全肾和激光捕获显微解剖(LCM)样品进行miRNA表达谱分析。使用的三个时间点是:(1)产后(PN)第21天,三色阳性区域发育之前;(2) PN28,三色染色最早的标志;(3)进展性纤维化后PN42的变化。PN21作为适当的对照,并作为比较miRNA表达谱的参考时间点。结果:LCM样品显示3个暂时上调的mirna [PN28为2 ~ 2.75倍,PN42为2.5 ~ 4倍(P≤0.05)]和4个暂时下调的mirna [PN28为2 ~ 2.75倍,PN42为2.75 ~ 5倍(P≤0.05)]。26个mirna的表达没有变化,直到PN42[6个减少(2.25 ~ 3.5倍)(P≤0.05),20个增加(2 ~ 4倍)(P≤0.05)]。在PLM的LCM样本中观察到的许多关键miRNA变化在对侧全肾中未见。结论:LCM精确取样可识别miRNA在肾间质纤维化(RIF)发生和发展过程中的变化。鉴定由这些mirna调控的靶蛋白将为纤维化过程提供新的见解,并确定独特的治疗靶点,以防止或减缓ADPKD中RIF的发生和进展。
{"title":"Unique interstitial miRNA signature drives fibrosis in a murine model of autosomal dominant polycystic kidney disease.","authors":"Ameya Patil,&nbsp;William E Sweeney,&nbsp;Cynthia G Pan,&nbsp;Ellis D Avner","doi":"10.5527/wjn.v7.i5.108","DOIUrl":"https://doi.org/10.5527/wjn.v7.i5.108","url":null,"abstract":"<p><strong>Aim: </strong>To delineate changes in miRNA expression localized to the peri-cystic local microenvironment (PLM) in an orthologous mouse model of autosomal dominant polycystic kidney disease (ADPKD) (<i>mcwPkd1<sup>(nl/nl)</sup></i> ).</p><p><strong>Methods: </strong>We profiled miRNA expression in the whole kidney and laser captured microdissection (LCM) samples from PLM in <i>mcwPkd1<sup>(nl/nl)</sup></i> kidneys with Qiagen miScript 384 HC miRNA PCR arrays. The three times points used are: (1) post-natal (PN) day 21, before the development of trichrome-positive areas; (2) PN28, the earliest sign of trichrome staining; and (3) PN42 following the development of progressive fibrosis. PN21 served as appropriate controls and as the reference time point for comparison of miRNA expression profiles.</p><p><strong>Results: </strong>LCM samples revealed three temporally upregulated miRNAs [2 to 2.75-fold at PN28 and 2.5 to 4-fold (<i>P</i> ≤ 0.05) at PN42] and four temporally downregulated miRNAs [2 to 2.75 fold at PN28 and 2.75 to 5-fold (<i>P</i> ≤ 0.05) at PN42]. Expression of twenty-six miRNAs showed no change until PN42 [six decreased (2.25 to 3.5-fold) (<i>P</i> ≤ 0.05) and 20 increased (2 to 4-fold) (<i>P</i> ≤ 0.05)]. Many critical miRNA changes seen in the LCM samples from PLM were not seen in the contralateral whole kidney.</p><p><strong>Conclusion: </strong>Precise sampling with LCM identifies miRNA changes that occur with the initiation and progression of renal interstitial fibrosis (RIF). Identification of the target proteins regulated by these miRNAs will provide new insight into the process of fibrosis and identify unique therapeutic targets to prevent or slow the development and progression of RIF in ADPKD.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 5","pages":"108-116"},"PeriodicalIF":0.0,"publicationDate":"2018-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i5.108","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36488715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Case of human immunodeficiency virus infection presenting as a tip variant of focal segmental glomerulosclerosis: A case report and review of the literature. 人类免疫缺陷病毒感染的病例表现为局灶节段性肾小球硬化的尖端变异:一个病例报告和文献回顾。
Pub Date : 2018-08-07 DOI: 10.5527/wjn.v7.i4.90
Daiki Goto, Naro Ohashi, Asumi Takeda, Yoshihide Fujigaki, Akira Shimizu, Hideo Yasuda, Kazuhisa Ohishi

The incidence of the collapsing variant of focal segmental glomerulosclerosis (FSGS) as a human immunodeficiency virus (HIV)-associated nephropathy has reduced since the introduction of antiretroviral therapy (ART). However, the incidence of other variants of FSGS, except for the collapsing variant, is increasing, and its therapeutic strategies remain uncertain. A 60-year-old HIV infected man in remission with ART was admitted for progressive renal insufficiency and nephrotic-ranged proteinuria. Renal biopsy revealed a tip variant of FSGS and his clinical manifestations resolved with corticosteroid therapy. HIV infected patients might develop non-collapsing FSGS, including tip variant of FSGS and corticosteroid therapy might be effective for them. A renal biopsy might be essential to determine the renal histology and to decide on corticosteroid therapy.

自引入抗逆转录病毒治疗(ART)以来,局灶节段性肾小球硬化(FSGS)塌陷变体作为人类免疫缺陷病毒(HIV)相关肾病的发病率已经降低。然而,除了塌陷变异外,FSGS的其他变异的发病率正在增加,其治疗策略仍不确定。一名接受抗逆转录病毒治疗缓解期的60岁艾滋病毒感染者因进行性肾功能不全和肾病范围蛋白尿入院。肾活检显示FSGS的尖端变异,其临床表现在皮质类固醇治疗后消失。HIV感染患者可能发生非塌陷性FSGS,包括FSGS的尖端变异,皮质类固醇治疗可能对其有效。肾活检可能是必要的,以确定肾脏组织学和决定皮质类固醇治疗。
{"title":"Case of human immunodeficiency virus infection presenting as a tip variant of focal segmental glomerulosclerosis: A case report and review of the literature.","authors":"Daiki Goto,&nbsp;Naro Ohashi,&nbsp;Asumi Takeda,&nbsp;Yoshihide Fujigaki,&nbsp;Akira Shimizu,&nbsp;Hideo Yasuda,&nbsp;Kazuhisa Ohishi","doi":"10.5527/wjn.v7.i4.90","DOIUrl":"https://doi.org/10.5527/wjn.v7.i4.90","url":null,"abstract":"<p><p>The incidence of the collapsing variant of focal segmental glomerulosclerosis (FSGS) as a human immunodeficiency virus (HIV)-associated nephropathy has reduced since the introduction of antiretroviral therapy (ART). However, the incidence of other variants of FSGS, except for the collapsing variant, is increasing, and its therapeutic strategies remain uncertain. A 60-year-old HIV infected man in remission with ART was admitted for progressive renal insufficiency and nephrotic-ranged proteinuria. Renal biopsy revealed a tip variant of FSGS and his clinical manifestations resolved with corticosteroid therapy. HIV infected patients might develop non-collapsing FSGS, including tip variant of FSGS and corticosteroid therapy might be effective for them. A renal biopsy might be essential to determine the renal histology and to decide on corticosteroid therapy.</p>","PeriodicalId":23745,"journal":{"name":"World Journal of Nephrology","volume":"7 4","pages":"90-95"},"PeriodicalIF":0.0,"publicationDate":"2018-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5527/wjn.v7.i4.90","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36381335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
World Journal of Nephrology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1